Skip to search formSkip to main contentSkip to account menu

Multiple Myeloma

Known as: Myeloma Multiple, multiple myeloma (MM), multiple myelomatosis 
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones… 
National Institutes of Health

Related topics

Related topics

50 relations
100 ML zoledronic acid 0.05 MG/ML Injection5 ML zoledronic acid 0.8 MG/ML InjectionAldesleukinAtypical lymphocyte

Broader (1)

Neoplasms

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Clonal competition with alternating dominance in multiple myeloma.
Emerging evidence indicates that tumors can follow several evolutionary paths over a patient's disease course. With the use of… 
Highly Cited
2008
Highly Cited
2008
IRF4 addiction in multiple myeloma
The transcription factor IRF4 (interferon regulatory factor 4) is required during an immune response for lymphocyte activation… 
Highly Cited
2007
Highly Cited
2007
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.
Acquired genomic aberrations have been shown to significantly impact survival in several hematologic malignancies. We analyzed… 
Highly Cited
2005
Highly Cited
2005
Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA.
A procedure is described for the large-scale purification of light (L) and heavy (H) chain mRNAs from plasmacytomas produced in… 
Highly Cited
2005
Highly Cited
2005
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
We have shown that the proteasome inhibitor bortezomib (formerly known as PS-341) triggers significant antitumor activity in… 
Highly Cited
2003
Highly Cited
2003
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
PURPOSE To evaluate the activity of thalidomide in patients with asymptomatic multiple myeloma and of thalidomide-dexamethasone… 
Highly Cited
2003
Highly Cited
2003
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
The proteasome inhibitor PS-341 inhibits nuclear factor-kappaB (NF-kappaB) activation, induces apoptosis in cancer cells… 
Highly Cited
2002
Highly Cited
2002
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.
Bone marrow plasma cells (PCs) from 74 patients with newly diagnosed multiple myeloma (MM), 5 with monoclonal gammopathy of… 
Highly Cited
1994
Highly Cited
1994
Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987.
This paper presents an analysis of data on the incidence of leukemia, lymphoma and myeloma in the Life Span Study cohort of… 
Highly Cited
1947
Highly Cited
1947
DISEASE
Background: Little is known about patients who frequently visit the emergency department (ED) for acute exacerbation of chronic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)